The Effect of a Pro-inflammatory Milieu on Tregalizumab ( BT-061 )-Induced Regulatory T-cell Activity

Background . Regulatory T cells (Tregs) are essential for maintaining normal immune homeostasis. We have previously reported that tregalizumab is a humanized, non-depleting, CD4 agonistic antibody that selectively activates Tregs. The specific functionality of tregalizumab may originate from the recognition of a unique epitope on domain 2 of CD4 that is not recognized by other anti-CD4 monoclonal antibodies. Tregalizumab is in clinical development for the treatment of rheumatoid arthritis (RA). Currently, a Phase IIb trial -TREAT 2bis in progress Effect of MTX in co-culture Effect of cytokines in co-culture Background BT-061 Abstract